Background
General treatment strategy for localized prostate cancer
External beam radiotherapy
Rationale for treating localized prostate cancer using hypo-fractionation
Treatment results with extreme hypo-fractionation
Methods/design
General study setting
Study design
Patient inclusion criteria
-
Histologically confirmed, locally confined prostate cancer
-
Completed staging according to the National Guidelines
-
Gleason score ≤ 7
-
PSA < 15 ng/ml
-
Prostate volume < 80 cm3
-
IPSS-Score ≤ 12
-
Age > 75 years or Age 70–75 years and either PSA > 10 ng/ml and/or Gleason score = 7b and/or Gleason score = 7a with > 33% positive biopsy cores and/or cT > 2a and/or prostate volume > 60 cm3
-
Informed consent
Patient exclusion criteria
-
Treatment in the PREFERE trial possible
-
Previous pelvic radiotherapy
-
Contraindication against the implantation of fiducial gold markers
-
Immunosuppressive therapy
-
Treatment relevant co-morbidities
-
Patient’s inability to understand or comply with the procedures
Treatment planning and delivery
Organ at risk | Dose limit |
---|---|
Rectum | Dmax < 38 Gy V36Gy < 1 cm3 & < 5% V29Gy < 15 cm3 & < 20% V18Gy < 25 cm3 & < 50% |
Bladder | Dmax < 38 Gy V36Gy < 10 cm3 & < 10% V18Gy < 40% |
Urethra | Dmax < 44 Gy |
Penile Bulb | V30Gy < 3 cm3 & < 50% |
Femoral Heads | V30Gy < 10 cm3
V14,5Gy < 5% |
Testicle | To be blocked for passing beams |
Small Bowel | V30Gy < 1 cm3
V18Gy < 5 cm3
|
Neurovascular Bundle | V38Gy < 50% |
Skin (5 mm) | Dmax < 30 Gy |